Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- S-P to Increase Its MRs to 600 to Detail Ribavirin
December 31, 2001
- GSK's Flutide Diskus Included in NHI Price List
December 31, 2001
- The Year 2001 in Retrospect:
December 31, 2001
- BUSINESS NEWS IN BRIEF
December 31, 2001
- Innovation and Reward - Contributing to a Healthy and Growing Economy
December 31, 2001
- Takara Shuzo Develops New Gene Transfer Technology, rPIC Method
December 31, 2001
- Perspective for 2002
December 31, 2001
- J&J: New Breast Cancer Biopsy System
December 31, 2001
- Disasters That Never Come
December 31, 2001
- Sugi Pharmacy to Maintain 30% Growth Rates
December 31, 2001
- Aiming to Enter Top 10 Next Year: Mr Dunoyer of GSK
December 31, 2001
- Fujisawa Licenses Tacrolimus-coated Stents to JOMED of Netherlands
December 31, 2001
- New Year's Greeting
December 31, 2001
- Appropriate Use of Insulin Explained: Novo Nordisk Seminar
December 31, 2001
- What Price Do Patients Pay?
December 31, 2001
- Chuikyo Approves Inclusion of Zithromac in NHI Price List
December 31, 2001
- Imigran Tablets Selling Better than Expected: GSK
December 24, 2001
- Health Minister Concerned About Higher Price of Reagent for Blood Test
December 24, 2001
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…